In this article
FDA Approval for Advanced Urothelial Cancer Combination Therapy
As of December 15, 2023, the Food and Drug Administration (FDA) approved enfortumab vedotin-ejfv (Padcev, Astellas Pharma) along with pembrolizumab (Keytruda, Merck) for people who have locally advanced or metastatic urothelial carcinoma (la/mUC). The FDA previously gave rapid approval to this combination for patients with locally advanced or metastatic urothelial carcinoma who cannot receive cisplatin-containing treatment.
EV-302 Clinical Trial Design and Patient Criteria
The study looked at how well it worked in EV-302/KN-A39 (NCT04223856), a randomized, open-label trial with 886 people who had locally advanced or metastatic urothelial carcinoma and had not had any systemic treatment for advanced illness before. Patients were randomly given either enfortumab vedotin-ejfv with pembrolizumab or platinum-based chemotherapy (gemcitabine with either cisplatin or carboplatin). Randomization was categorized based on cisplatin eligibility, PD-L1 expression, and the existence of liver metastases.
Significant Survival and Progression Outcomes
The primary efficacy measures were overall survival (OS) and progression-free survival (PFS), evaluated by an impartial central review team without bias.
Enfortumab vedotin-ejfv plus pembrolizumab showed statistically significant improvements in overall survival (OS) and progression-free survival (PFS) compared to platinum-based treatment. The median overall survival was 31.5 months (95% CI: 25.4, not estimable) for patients treated with enfortumab vedotin-ejfv plus pembrolizumab and 16.1 months (95% CI: 13.9, 18.3) for those who underwent platinum-based chemotherapy. The hazard ratio was 0.47 (95% CI: 0.38, 0.58) with a p-value of less than 0.0001. The median progression-free survival (PFS) was 12.5 months (95% CI: 10.4, 16.6) for patients treated with enfortumab vedotin-ejfv plus pembrolizumab and 6.3 months (95% CI: 6.2, 6.5) for those who underwent platinum-based chemotherapy. The hazard ratio (HR) was 0.45 (95% CI: 0.38, 0.54) with a p-value of less than 0.0001.
Common Side Effects and Adverse Reactions
The most frequent adverse reactions (≥20%) observed in patients treated with enfortumab vedotin-ejfv in combination with pembrolizumab included various laboratory abnormalities such as increased aspartate aminotransferase, increased creatinine, rash, increased glucose, peripheral neuropathy, increased lipase, decreased lymphocytes, increased alanine aminotransferase, decreased hemoglobin, fatigue, decreased sodium, decreased phosphate, decreased albumin, pruritus, diarrhea, alopecia, decreased weight, decreased appetite, increased urate, decreased neutrophils, decreased potassium, dry eye, nausea, constipation, increased potassium, dysgeusia, urinary tract infection, and decreased platelets.
Recommended Dosage and Administration Guidelines
The suggested dosage of enfortumab vedotin-ejfv in combination with pembrolizumab is 1.25 mg/kg (up to 125 mg for patients weighing 100 kg or more) given as an intravenous infusion lasting 30 minutes on Days 1 and 8 of a 21-day cycle until disease progression or intolerable side effects.
The suggested dosage of pembrolizumab when combined with enfortumab vedotin-ejfv is 200 mg given through intravenous infusion every 3 weeks or 400 mg every 6 weeks until disease advancement, intolerable toxicity, or two years of treatment.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Susan Hau
Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy. Hau's expertise lies in cancer cell biolo…
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.